E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
about
Oncolytic Replication of E1b-Deleted AdenovirusesOncolytic adenovirus-mediated therapy for prostate cancerAdenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-regionAttraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunityCombination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Genetic identification of adenovirus type 5 genes that influence viral spread.A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKsVirus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in miceOncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice.Oncolytic viral therapies.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAILTargeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus ImmunotherapyCEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells.Homologous recombination in E3 genes of human adenovirus species DLister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerAdenoviral vector-based strategies for cancer therapy.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirusSwitching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.Adenovirus Modulates Toll-Like Receptor 4 Signaling by Reprogramming ORP1L-VAP Protein Contacts for Cholesterol Transport from Endosomes to the Endoplasmic Reticulum.Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinomaNovel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs.A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy.GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
P2860
Q26777406-9F2A5EBD-1C42-4A88-A93D-41B109AD27E7Q27004796-F1DE6070-A2FD-49B3-8CD0-0E2636BE04F5Q28484203-5A4C1B75-E828-4263-B613-A18053183848Q33713956-5AAE023C-40BC-4091-B566-9068326BE0D2Q33906116-82B76C69-E1DE-4F61-9C46-7A7CC817611DQ34096503-A5C300A5-5F3F-4D65-8A41-7753A6E92DD4Q34293923-0F48C82B-CC36-4E8D-A176-D1218315129CQ34343742-DCE50A95-2CD4-4A02-956A-400D8C0E5122Q34353556-8A0B4D83-5AED-4804-AEA8-0A3CFFDA4F7FQ35145614-490EB0B3-28F2-445F-B75F-9EE0F1E5750BQ35572421-BED2FAE9-A988-4160-B8D1-0C2C34E15CF7Q35811062-2B51B1E4-C7CD-4D92-956C-21D07E331B19Q35852258-818A1F05-F7DF-4B74-9C17-BAB23152C822Q36099082-3FD4FEAB-34E1-4B26-8BF1-D1EC534A2C0FQ36209190-FBB81023-4BA9-4778-A422-E96D1503CBD6Q36488714-D36E8857-83D3-4DD8-ABBD-383662CCB4A7Q36594178-CC5E6AFB-7061-449F-A61C-DCC60DE48185Q36738884-A66D99DB-CA82-46C3-90E7-635EFE1E96D6Q36753953-5713432C-9E08-4095-8791-54A75A2DDF05Q37209263-F22A0C7F-B822-4BE7-979E-CFCCD7528D9BQ37254362-1EBADFC8-5A1C-47F6-9875-6A9C1C43F2CAQ37389574-F27479AD-3E85-48D7-B2E7-A7A005F892A7Q37409025-938CEABB-C9D5-4CCE-8737-BAD9429B45A7Q37448942-601BA33C-C0DA-489A-8056-7CD707EA4D00Q37547013-1106E79C-0C9F-4DD2-BFE0-1AEEDCE2C7F3Q37547783-4D10486E-7E55-42F8-8BDE-1D07AAAA488FQ37564490-E12D98E1-443F-4C83-B4E8-6036DA743A68Q38033591-0343C375-7E13-487E-B508-7F85DE158980Q38702903-AEB3F051-18FF-43ED-A084-419E50DCD9A7Q38721817-DC73B4DF-70C9-414D-9FBE-FE06E305F838Q38886874-0A596C07-506D-452D-A811-0E5F1BDBBC73Q38964488-E1CD2C2F-CBCF-459C-830F-E7B9FC03B1A3Q39135464-A91F4578-35BE-4523-B753-1C0F472B78DAQ39423631-DFEFEC2B-B772-4B5A-816D-DAF4EC0F25EEQ39437927-5B88FC4E-AC46-4D00-B67E-15C95D2FA89AQ39442539-3089F524-A65E-4653-8096-F0E6FB39ED24Q39462851-10FF91DA-3D84-49D3-916F-156E94D63444Q39491356-7561EAC9-8806-47DE-B623-EF5E311D0EDBQ39735941-57EA662F-8243-4144-ABDC-9568BF8874D4Q39752863-22E5D39E-122F-42C1-99F1-8E9C004378AC
P2860
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
E3 gene manipulations affect o ...... immunocompetent tumor models.
@en
type
label
E3 gene manipulations affect o ...... immunocompetent tumor models.
@en
prefLabel
E3 gene manipulations affect o ...... immunocompetent tumor models.
@en
P2093
P356
P1433
P1476
E3 gene manipulations affect o ...... immunocompetent tumor models.
@en
P2093
Arthi Anand
David Kirn
Gabriel Brooks
Gunnel Hallden
Jennelle Francis
Nick Lemoine
Ta-Chiang Liu
Yaohe Wang
P2888
P304
P356
10.1038/NBT887
P50
P577
2003-10-12T00:00:00Z
P5875
P6179
1043212288